$MNOV
MEDICINOVA INC

2017 Q2 Form 10-K Financial Statement

#000156459018001957 Filed on February 13, 2018

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2017
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.910M $2.120M $8.800M
YoY Change -14.73% -8.62% 19.57%
% of Gross Profit
Research & Development $800.0K $800.0K $3.900M
YoY Change -11.11% -20.0% 25.81%
% of Gross Profit
Depreciation & Amortization $0.00 $7.217K $28.10K
YoY Change -100.0% 75.81% 98.9%
% of Gross Profit
Operating Expenses $2.805K $3.024K $13.03M
YoY Change -12.48% -10.85% 19.71%
Operating Profit -$2.805M -$3.024M -$13.03M
YoY Change -12.47% -10.85% 19.71%
Interest Expense $20.00K $20.00K $298.00
YoY Change 0.0% 100.0% -34.36%
% of Operating Profit
Other Income/Expense, Net -$10.00K $0.00 -$25.60K
YoY Change 0.0% -45.57%
Pretax Income -$2.787M -$3.012M -$12.94M
YoY Change -12.87% -10.88% 19.13%
Income Tax $0.00 $4.060K -$1.744M
% Of Pretax Income
Net Earnings -$2.789K -$3.017K -$11.16M
YoY Change -12.82% -10.79% 2.73%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$80.52K -$87.46K -$317.6K
COMMON SHARES
Basic Shares Outstanding 34.53M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.90M $21.60M $28.00M
YoY Change -13.91% -21.74% 16.18%
Cash & Equivalents $22.89M $21.64M $28.00M
Short-Term Investments
Other Short-Term Assets $500.0K $700.0K $300.0K
YoY Change -28.57% -36.36% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.40M $22.30M $28.30M
YoY Change -13.97% -22.3% 14.57%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $100.0K $100.0K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $600.0K $600.0K $600.0K
YoY Change 0.0% -14.29% 0.0%
Other Assets $0.00
YoY Change
Total Long-Term Assets $15.10M $15.12M $15.10M
YoY Change -0.66% -0.5% 0.0%
TOTAL ASSETS
Total Short-Term Assets $23.40M $22.30M $28.30M
Total Long-Term Assets $15.10M $15.12M $15.10M
Total Assets $38.50M $37.42M $43.40M
YoY Change -9.2% -14.75% 9.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $158.1K $1.500M
YoY Change 50.0% 58.14% 275.0%
Accrued Expenses $1.100M $863.8K $1.400M
YoY Change 0.0% -13.62% 7.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.400M $1.022M $2.900M
YoY Change 7.69% -2.65% 81.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.700M $1.700M $1.700M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $1.700M $1.700M $1.700M
YoY Change 0.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.400M $1.022M $2.900M
Total Long-Term Liabilities $1.700M $1.700M $1.700M
Total Liabilities $5.070M $4.673M $4.800M
YoY Change 1.4% -0.96% -9.43%
SHAREHOLDERS EQUITY
Retained Earnings -$336.1M -$333.3M
YoY Change 3.1% 3.25%
Common Stock $369.6M $366.2M
YoY Change 1072138.83% 1135652.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.39M $32.75M $38.60M
YoY Change
Total Liabilities & Shareholders Equity $38.46M $37.42M $43.40M
YoY Change -9.22% -14.67% 9.05%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2017
OPERATING ACTIVITIES
Net Income -$2.789K -$3.017K -$11.16M
YoY Change -12.82% -10.79% 2.73%
Depreciation, Depletion And Amortization $0.00 $7.217K $28.10K
YoY Change -100.0% 75.81% 98.9%
Cash From Operating Activities -$1.410M -$2.550M -$6.924M
YoY Change -5.37% 5.37% 5.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.660M 70.00K 10.80M
YoY Change 504.55% -99.12% 24.6%
NET CHANGE
Cash From Operating Activities -1.410M -2.550M -6.924M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 2.660M 70.00K 10.80M
Net Change In Cash 1.250M -2.480M 3.873M
YoY Change -217.92% -144.77% 90.33%
FREE CASH FLOW
Cash From Operating Activities -$1.410M -$2.550M -$6.924M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$1.410M -$2.550M -$6.924M
YoY Change -4.73% 4.42% 4.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-8845079
CY2016 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
3519172
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7362662
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5805217
CY2015 us-gaap Operating Expenses
OperatingExpenses
8822386
CY2017 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
4223746
CY2015 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
54206
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1788
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8846867
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10859214
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-10865979
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-11163136
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
3000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4133969
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
172585
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
687367
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4432017
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.27
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.69
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
15153
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35137028
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3754
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8837720
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-13027093
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1744050
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8803347
CY2017 us-gaap Operating Expenses
OperatingExpenses
13027093
CY2016 us-gaap Operating Expenses
OperatingExpenses
10881834
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-10881834
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-8822386
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10862225
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7359
CY2017Q4 us-gaap Assets
Assets
43419064
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1520225
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1360744
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
380156510
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
364886468
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36452893
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34523678
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36452893
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34523678
CY2015 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
3017169
CY2017 us-gaap Interest Expense
InterestExpense
298
CY2016 us-gaap Interest Expense
InterestExpense
454
CY2015 us-gaap Interest Expense
InterestExpense
514
CY2015 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
39386
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15993683
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
426013
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
89909
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2025500
CY2017 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
25303
CY2016 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
46584
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
22010589
CY2015 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
607528
CY2015 mnov Warrant Exercises
WarrantExercises
872632
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
32752974
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3972533
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
87729
CY2016 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
159529
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
829526
CY2016 mnov Warrant Exercises
WarrantExercises
7588852
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4474945
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
77319
CY2017 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
9891315
CY2017 mnov Warrant Exercises
WarrantExercises
402378
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
4474945
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3972533
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2025500
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28098
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14127
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26704
CY2016 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
-1901
CY2017 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1673
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-32139
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-34319
CY2017 mnov Increase Decrease In Receivables Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInReceivablesPrepaidDeferredExpenseAndOtherAssets
-242064
CY2016 mnov Increase Decrease In Receivables Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInReceivablesPrepaidDeferredExpenseAndOtherAssets
-175495
CY2015 mnov Increase Decrease In Receivables Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInReceivablesPrepaidDeferredExpenseAndOtherAssets
284538
CY2017 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
1246630
CY2016 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
127373
CY2015 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-109276
CY2017 mnov Increase Decrease In Deferred Tax Liability Deferred Revenue And Other Long Term Liabilities
IncreaseDecreaseInDeferredTaxLiabilityDeferredRevenueAndOtherLongTermLiabilities
-1754208
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6923934
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6546213
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7152370
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84483
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-84483
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2320
CY2017 mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptionsAndWarrantsNetOfIssuanceCosts
10719707
CY2015 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
89909
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10797026
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8665636
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17563752
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
614
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
6348
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1748
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3873706
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2041288
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10407314
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22076749
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11669435
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
9203
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
6035
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
7443
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3100000
CY2014 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
240419
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
11042
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations and Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in U.S. government securities. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.</p></div>
CY2015 us-gaap License Costs
LicenseCosts
300000
CY2017Q4 mnov Working Capital Net
WorkingCapitalNet
25400000
CY2017Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2016 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2015 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3900000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2700000
CY2017 us-gaap License Costs
LicenseCosts
300000
CY2016 us-gaap License Costs
LicenseCosts
400000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3447969
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
689000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1158000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1195000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
105579
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7400
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5514038
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4252201
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6264038
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5499084
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9740336
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
15742
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
20157
CY2017Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
233441
CY2016Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
284585
CY2017Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
285418
CY2016Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
285375
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
534601
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
590117
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
471715
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
499400
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
952470
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
882090
CY2017Q4 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
122665
CY2016Q4 mnov Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
191343
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
144105
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
43767
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
141504
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
145600
CY2017 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P4Y1M
CY2017 mnov Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2021-12
CY2017 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
254593
CY2016 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
256314
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
253
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
211663
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
187574
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
142703
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
148419
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
690359
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1200000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5514038
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.00
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.14
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.00
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.81
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.27
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.03
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
426013
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
829526
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7663602
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7677000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2384000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
572000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
777000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
71226000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
198164
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
414572
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M29D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M10D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13600000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11500000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12900000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9200000
CY2016 mnov Stock Issuance Limit Under Employee Stock Purchase Plan Description
StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription
Shares reserved automatically increase each year by a number equal to the lesser of: (i)15,000 shares; (ii)1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii)such lesser amount as determined by the Board
CY2016 mnov Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.78
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.64
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.08
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M28D
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12940362
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10892275
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-8866201
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
33176
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
30050
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
28481
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12907186
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10862225
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8837720
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-1489
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-412
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
10158
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
5655
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
7359
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
10158
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3754
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
7359
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1329888
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-424320
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1754208
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59480000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
90211000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
88900000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
429000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
838000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1084000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8160000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7776000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2585000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2624000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
763000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101986000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101048000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1343000
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1956000
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1956000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1343000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
3205
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
2845
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3382
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3199
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2836
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3382
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3199
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2836
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
3406
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3755
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-1602
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3755
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1602
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2017Q4 mnov Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Valuation Allowance Change In Amount
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetValuationAllowanceChangeInAmount
33400000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1956000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1956000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
69883000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
100030000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
99092000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70086000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101986000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101048000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
203000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1956000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1956000
CY2017 mnov Increase In Ownership Percentage
IncreaseInOwnershipPercentage
0.50
CY2017 mnov Cumulative Stock Ownership Change Period
CumulativeStockOwnershipChangePeriod
P3Y
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.350
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.011
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.009
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.014
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
2.474
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.084
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.135
CY2017 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.003
CY2016 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.001
CY2015 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.001
CY2017 mnov Effective Income Tax Rate Reconciliation Expiration Of Attributes
EffectiveIncomeTaxRateReconciliationExpirationOfAttributes
-0.187
CY2016 mnov Effective Income Tax Rate Reconciliation Expiration Of Attributes
EffectiveIncomeTaxRateReconciliationExpirationOfAttributes
-0.172
CY2015 mnov Effective Income Tax Rate Reconciliation Expiration Of Attributes
EffectiveIncomeTaxRateReconciliationExpirationOfAttributes
-0.246
CY2017 mnov Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017
-2.537
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.029
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.136
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.034
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.135
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2017 mnov Percentage Of Net Operating Loss Deduction With Tax
PercentageOfNetOperatingLossDeductionWithTax
0.80
CY2017 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Under the Act, NOL deductions are limited to 80% of taxable income in future periods and NOLs can be carried forward indefinitely.
CY2017Q4 mnov Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Change In Amount
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetChangeInAmount
32700000
CY2017 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
100000
CY2017 mnov Cumulative Foreign Earnings
CumulativeForeignEarnings
200000
CY2017Q4 mnov Deferred Tax Benefit On Revaluation Of Deferred Income Tax Assets And Liabilities
DeferredTaxBenefitOnRevaluationOfDeferredIncomeTaxAssetsAndLiabilities
600000
CY2017 mnov Deferred Tax Benefit Reassessed
DeferredTaxBenefitReassessed
1100000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
65995
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
66289
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
64749
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3024
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
2805
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
3792
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3017
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-2789
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3017
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2789
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
3392
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
1440
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1449
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1449
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04

Files In Submission

Name View Source Status
0001564590-18-001957-index-headers.html Edgar Link pending
0001564590-18-001957-index.html Edgar Link pending
0001564590-18-001957.txt Edgar Link pending
0001564590-18-001957-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018021321065846230113.jpg Edgar Link pending
mnov-10k_20171231.htm Edgar Link pending
mnov-20171231.xml Edgar Link completed
mnov-20171231.xsd Edgar Link pending
mnov-20171231_cal.xml Edgar Link unprocessable
mnov-20171231_def.xml Edgar Link unprocessable
mnov-20171231_lab.xml Edgar Link unprocessable
mnov-20171231_pre.xml Edgar Link unprocessable
mnov-ex231_7.htm Edgar Link pending
mnov-ex311_6.htm Edgar Link pending
mnov-ex312_11.htm Edgar Link pending
mnov-ex321_8.htm Edgar Link pending
mnov-ex322_10.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending